舒肝解郁胶囊治疗轻中度类风湿关节炎伴轻中度抑郁症的临床疗效研究  

Clinical Efficacy of Shugan Jieyu Capsules in Treating Mild to Moderate Rheumatoid Arthritis with Depression

作　　者：李学荣[1] 杨毅[1] 张榜硕[1] 方秋实 邓玲[1] 徐辉[1] 陈永平[1] LI Xue-rong;YANG Yi;ZHANG Bang-shuo;FANG Qiu-shi;DENG Ling;XU Hui;CHEN Yong-ping(Department of Hematology and Rheumatology,Chongqing Three Gorges Central Hospital,Chongqing 404000;Department of Critical Care Medicine,Chongqin 404000)

机构地区：[1]重庆三峡中心医院血液风湿科,重庆404000 [2]重庆三峡中心医院重症医学科,重庆404000

出　　处：《世界中西医结合杂志》2021年第1期157-161,共5页World Journal of Integrated Traditional and Western Medicine

基　　金：重庆市卫计委中医药科技项目(ZY201702116)。

摘　　要：目的观察舒肝解郁胶囊治疗轻中度类风湿关节炎(rheumatoid arthritis,RA)伴轻中度抑郁症的有效性以及安全性。方法本研究采用病例对照的方法,选取2017年5月—2018年12月期间重庆三峡中心医院血液风湿科门诊及住院的轻中度RA伴轻中度抑郁症患者120例,随机分为空白组、治疗组、对照组,每组各40例。三组患者均予以非甾体抗炎药(non-steroidal anti-inflammatory drugs,NSAIDs)及慢作用抗RA药(disease modifying antirheumatic drugs,DMARDs)基础治疗,治疗组给予舒肝解郁胶囊治疗,对照组给予帕罗西汀治疗,三组患者均连续给药24周。三组患者分别于治疗前、治疗2、8、12、24周后对三组患者进行疾病活动性评分-28(disease activity score-28,DAS28)、汉密尔顿抑郁量表(Hamilton’s depression scale,HAMD)评分、抑郁自评量表(self-rating depression scale,SDS)评分,通过评分比较其临床疗效及不良反应。结果三组患者治疗8、12、24周后DAS28评分均较治疗前明显下降(P<0.05);且治疗组和对照组治疗8、12、24周后DAS28评分较空白组同一时间节点下降(P<0.05),但对照组与治疗组DAS28评分比较差异无统计学意义(P>0.05)。对照组和治疗组患者治疗2、8、12、24周后HAMD量表评分均较治疗前明显降低(P<0.05);且对照组和治疗组患者治疗2、8、12、24周后HAMD量表评分均较空白组同一时间节点明显下降(P<0.05),但对照组与治疗组的HAMD量表评分比较差异无统计学意义(P>0.05)。对照组和治疗组患者治疗2、8、12、24周后SDS量表评分均较治疗前明显降低(P<0.05);且对照组和治疗组患者治疗2、8、12、24周后SDS量表评分均较空白组同一时间节点明显下降(P<0.05),但对照组与治疗组的SDS量表评分比较差异无统计学意义(P>0.05)。对照组和治疗组均未发生明显的不良反应。结论舒肝解郁胶囊治疗轻中度RA伴轻中度抑郁症患者,与帕罗西汀疗效相当,可协同抗RA药�Objective To observe the efficacy and safety of Shugan Jieyu capsules in treating mild to moderate rheumatoid arthritis(RA)with mild to moderate depression.Methods A case-control study was conducted.From May2017 to December 2018,120 patients with mild to moderate RA in the Department of Hematology and Rheumatology of Chongqing Three Gorges Central Hospital were selected and randomly divided into blank group and treatment group.,Control group,40 cases in each group.The three groups of patients were given basic treatment with non-steroidal anti-inflammatory drugs(NSAIDs)and slow-acting anti-RA drugs(disease modifying antirheumatic drugs,DMARDs),and the treatment group was given Shugan Jieyu capsule treatment,control One group was given paroxetine treatment,and the three groups were given continuous treatment for 24 weeks.The three groups of patients were treated with disease activity score-28(DAS28)and Hamilton’s depression scale(HAMD)before treatment and 2,8,12,and 24 weeks after treatment.Score,self-rating depression scale(SDS)score,and compare its clinical efficacy and adverse reactions through scores.Results The DAS28 scores of the three groups of patients after 8,12,and 24 weeks of treatment were significantly lower than those before the treatment(P<0.05);and the DAS28 scores of the treatment group and the control group after 8,12,and 24 weeks of treatment were lower than the blank group at the same time node(P<0.05),but there was no significant difference in DAS28 score between the control group and the treatment group(P>0.05).The HAMD scale scores of the patients in the control group and the treatment group after 2,8,12,and 24 weeks of treatment were significantly lower than those before the treatment(P<0.05);and the patients in the control group and the treatment group were HAMD after 2,8,12,and 24 weeks of treatment The scale scores were significantly lower than those of the blank group at the same time(P<0.05),but there was no significant difference between the control group and the treatment group in t

关 键 词：舒肝解郁胶囊 类风湿关节炎 抑郁 

分 类 号：R593.22[医药卫生—内科学] R749.4[医药卫生—神经病学与精神病学]